Age Related Macular Degeneration Market Size and Share - Growth Analysis Report and Forecast Trends 2026-2030

AMD is a progressive retinal disorder divided into dry AMD, which accounts for the majority of cases, and the less common but more aggressive wet AMD. Current standards of care for wet AMD center on intravitreal anti-VEGF injections, while dry AMD management has historically been limited to AREDS-based nutritional supplementation. The market reached approximately $13.14 billion in 2025 and is currently estimated at around $14.108 billion in 2026, with projected 7.37% compound annual growth driven by new therapeutic approvals and demographic aging. Treatment-related products account for the largest share of revenue, with diagnostic devices and screening services representing smaller but rapidly growing adjacencies.

Demographic aging is the single most powerful tailwind, as AMD prevalence rises sharply after age 60 and population over 65 is expanding in nearly every major economy. Expanded reimbursement coverage and earlier diagnosis through optical coherence tomography and AI-enabled screening are enlarging the eligible patient base. A robust late-stage pipeline, including complement inhibitors, gene therapies, and longer-acting anti-VEGF formulations, is expected to unlock the historically underserved dry AMD segment and extend treatment intervals for wet AMD.

By disease type, wet AMD dominates current revenue but dry AMD is forecast to deliver faster growth as the first disease-modifying approvals reach market. By product category, anti-VEGF agents lead, with Eylea and Lucentis as flagship brands, while emerging categories include biosimilars, sustained-release implants, and small-molecule therapies. North America holds the largest regional share due to high diagnosis rates and reimbursement depth, followed by Europe, while Asia-Pacific is the fastest-growing region driven by rising healthcare access in China, Japan, and India.

What are the recent trends and outlook?

The most consequential trend is the anticipated arrival of disease-modifying therapies for dry AMD, beginning with complement pathway inhibitors, which could more than double the addressable patient population over the forecast period. Longer-acting and sustained-release anti-VEGF formulations aim to reduce treatment burden and improve adherence, which has historically been a key limit on real-world outcomes. Combination therapies pairing anti-VEGF agents with novel mechanisms and gene therapy approaches represent the next frontier, with the global market projected to surpass $23 billion by the early 2030s.